![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 2, 1217-1222, January 11, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of
Received for publication, October 5, 2001, and in revised form, November 1, 2001
The Pax gene family encodes DNA-binding proteins
that can both activate and repress transcription of specific target
genes during embryonic development. Pax proteins are required
for pattern formation and cell differentiation in a broad spectrum of
developing tissues. Consistent with its expression in the
intermediate mesoderm, the optic cup and stalk, and the otic vesicle,
Pax2, a member of the Pax2/5/8 subfamily, is essential for
the development of the renal epithelia, the optic cup, and the inner
ear. In addition to a DNA binding domain, the Pax2 protein contains a
carboxyl-terminal transactivation domain rich in serine, threonine, and
tyrosine. In this report, we demonstrate that the Pax2 transactivation
domain is phosphorylated by the c-Jun N-terminal kinase, but not the ERK1/2 or p38 MAP kinases and that phosphorylation is coincident with
increased transactivation of a Pax2-dependent reporter
gene. Activation of JNK by either upstream kinase MEKK1 or DLK or by expression of Wnt signaling proteins significantly enhances Pax2 phosphorylation in cells. In vitro kinase assays using
immunoprecipitated JNK or constitutively active, recombinant JNK show
phosphorylation of GST-Pax2 fusion proteins. In transfected cells,
phosphorylation of Pax2 correlates with increased transactivation of a
Pax2-dependent reporter gene, suggesting that
serine/threonine phosphorylation of the transactivation domain is
important for Pax2 activity. Pax2 can form a complex with the JNK
scaffolding protein JIP1, and this interaction is enhanced by
activation of the JNK signaling module with the upstream kinase
DLK. The data demonstrate that Pax2 is a new target for the JNK
signaling module and point to a novel mechanism for mediating
Pax-dependent transcription regulation.
The Pax family of genes encodes transcription factors with
conserved DNA binding motifs that are required for embryonic
development of a variety of tissues in Drosophila, mouse,
and humans. In vertebrates, Pax genes can be subdivided into classes
based on similar features and embryonic expression patterns (1). The
Pax2/5/8 subfamily is characterized by an amino-terminal-paired domain,
a conserved octapeptide sequence with similarity to the engrailed
homology domain (EH-1), and a partial-paired type homeobox. Pax2/5/8
proteins are transcription regulators that bind DNA via the
amino-terminal-paired domain, whereas the carboxyl-terminal region is
required for transactivation of target genes (2, 3).
In mouse and man, the Pax2 gene is essential for
the development of the kidneys (4), optic cup, and inner ear (5).
Pax2 encodes at least two alternatively spliced messages
that produce proteins of 392 and 415 amino acids, differing only by a
23 amino acid insertion (6). Genes known to be up-regulated by Pax2 include WT1 (7) and gdnf (8) in the developing
kidney and engrailed-2 (9) in the developing hindbrain. In
transfected cells, transcription activation requires the Pax2
carboxyl-terminal domain that is rich in serine and threonine residues,
which may be potential sites for phosphorylation. In the zebrafish Pax6 protein, the carboxyl-terminal transactivation domain is phosphorylated at multiple serine residues by the mitogen-activated protein kinases (MAPK)1 p38 MAPK and ERK1/2
to increase the transactivation potential (10). Of the Pax2/5/8
subfamily, only Pax8 has been studied with respect to phosphorylation,
though it is not clear which kinases are involved (11). MAP kinase
cascades are involved in transmitting signals generated at the cell
surface into the cytosol and nucleus and consist of three sequentially
acting enzymes: a MAP kinase, an upstream MAP kinase kinase (MEK), and
a MEK kinase (MEKK) (12, 13). The extracellular signal-regulated kinase 1/2 (ERK 1/2), the c-Jun N-terminal kinase/stress-activated protein kinases (JNK/SAPK), or the p38MAP kinases, can translocate to the
nucleus and subsequentely phosphorylate a variety of transcription factors. MEKK1 phosphorylates MKK4/MKK7 to activate JNK but can also
activate ERK and p38 MAPK in transfected cells.
This report addresses the phosphorylation state of the Pax2 protein and
its ability to activate transcription. We show that the
carboxyl-terminal activation domain is phosphorylated at serine and
threonine residues and that Pax2 phosphorylation is coincident with the
enhanced ability to transactivate a reporter gene. Pax2 is a substrate
for the c-Jun N-terminal kinase (JNK) but, unlike Pax6, is not
phosphorylated by ERK or p38 MAPK. Activation of JNK by either the
upstream kinases MEKK1 or DLK or by expression of Wnt signaling
proteins increases Pax2 phosphorylation and enhances the Pax2
transactivation potential. The data point to an important role for JNK
in modifying the Pax2 transactivation domain and stimulating
Pax2-dependent gene expression.
DNA Constructs--
The CMV-Pax-2bHA and carboxyl-terminal
deletions and the PRS4-CAT reported plasmid, containing five tandem
copies of the pax2 binding site PRS4 cloned upstream of the herpes
simplex virus thymidine kinase promoter, were as described (3). The
CMV-MEKK1 wild-type, CMV-MEKK1 K432M, HA-DLK, Myc-Erk, FLAG-JNK,
Myc-p38 MAPK, were provided by L. Holzman. The Myc-JIP1 was a gift of B. Margolis. The Wnt4 (gift of A. McMahon), Wnt11, and Wnt7a (IMAGE Consortium) coding sequences were cloned into CMV-CB6 and sequenced for
verification. The Pax2-GST fusion protein contained amino acids
197-415 and was purified by affinity to glutathione-agarose. GST-Elk
(Cell Signaling Technology, cat. no. 9184S) and GST-ATF-2 (Cell
Signaling Technology, cat. no. 9224S) were obtained commercially. GST-c-Jun (1) was as described (14). Constitutively active, recombinant JNK was purchased from Upstate Biotechnology (Lake Placid, NY).
Antibodies--
The antibodies used in this paper were: Pax-2
(6) 1:3000; FLAG (M5 monoclonal antibody, Sigma, 1:2000); HA (16B12,
BAbCO, 1:2000); Myc (9E10, BAbCO, 1:2000); phospho-JNK
(Thr-183/Tyr-185, Cell Signaling Technology, 1:2000); phospho-Erk1/2
(Thr-202/Tyr-204, Cell Signaling Technology, 1:2000); phospho-p38 MAPK
(Thr-180/Tyr-182, Cell Signaling Technology, 1:2000); phospho-c-Jun
(Ser-63, Cell Signaling Technology, 1:2000); JNK (Cell Signaling
Technology, 1:2000); Transient Transfection--
293 cells were cultured in
Dulbecco's modified Eagles medium (glucose concentration: 450 mg/dl)
supplemented with heat-inactivated 10% fetal bovine serum and 100 units/ml penicillin and 100 mg/ml streptomycin under humidified 5%
CO2, 95% air at 37 °C. Subconfluent cells were
transfected using 2-3 µg of plasmid DNA and 6 µl of FuGene 6 as
described by the manufacturer (Roche Molecular Biochemicals). Cells
were harvested 48-h post-transfection.
Western Blot--
Western blots were performed with equal
amounts of protein obtained by lysis of transiently transfected cells
in PK lysis buffer (50 mM HEPES pH 7.5, 150 mM
NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM Na3VO4, 50 mM NaF,
1% Triton X-100, 10% glycerol, and a mixture of protease inhibitors
(Roche Molecular Biochemicals, cat no. 1836170). The lysates were
separated by SDS-PAGE and immunoblotted with antibodies indicated in
the legends. Horseradish peroxidase-conjugated secondary antibodies
were used to detect antigen-antibody complexes by ECL detection system
(Amersham Biosciences).
Immunolinked Kinase Assays--
Cells were lysed in PK lysis
buffer after 40 h of transient transfection. After incubation with
antibodies against the epitope of the protein, the immunocomplex was
adsorbed to protein-G-Sepharose and washed with kinase buffer (25 mM HEPES, pH 7.4, 20 mM MgCl2, 0.5 mM EGTA, 12.5 mM In Vivo Labeling--
293 cells were transfected with expression
plasmids as indicated in the legends. The cells were cultured in
phosphate-free Dulbecco's modified Eagle's medium for 2 h after
40 h of transient transfection, and then labeled with 250 µCi of
[32P]orthophosphate for 4 h. After washing with cold
phosphate-buffered saline, lysates were prepared using lysis buffer and
then incubated with anti-HA antibodies at 4 °C for 2 h. The
immunocomplexes were adsorbed to protein G-Sepharose and were subjected
to SDS-PAGE followed by blotting onto nitrocellulose and
autoradiography. The amount of Pax2 that was immunoprecipitated was
assessed by re-immunoblotting of the nitrocellulose. For amino acid
analysis, immunoprecipitated Pax2 was blotted to polyvinylidene
difluoride membranes, excised, soaked in methanol, and subsequently
hydrolyzed in 6 N HCl for 2 h at 110 °C. Samples
were dried, washed repeatedly with water, and spotted onto thin layer
chromatography cellulose plates with fluorescent markers for Ser(P),
Thr(P), and Tyr(P). The plates were electrophoresed for 1 h at
1000 V, air-dried, sprayed with acetone to visualize markers, and
exposed to film.
Immunoprecipitation of JNK Module--
293 cells were
transfected with the expression plasmids as indicated in the legends.
After 40 h, lysates were prepared in IP buffer (20 mM
Tris-HCl pH 8.0, 100 mM NaCl, 0.5% Triton X-100, 10 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor
mixture). Lysates were incubated with anti-Myc M5 monoclonal antibodies
for 2 h at 4 °C. Antibodies were captured with protein
G-Sepharose for 1 h and washed three times with IP-wash (same as
IP buffer except 0.1% Triton X-100). Proteins were eluted from protein
G-Sepharose by boiling in 2× SDS-PAGE sample buffer.
Transient Transactivation Assays--
For 5 × 105 of 293 cells, 0.5 µg of CAT reporter plasmid was
cotransfected with various doses of effector plasmid and 0.25 µg of
p-CH110, a Pax2 Is a Substrate for the c-Jun N-terminal Kinase--
The
activation domain of Pax2 contains multiple serine, threonine, and
tyrosine residues that could serve as potential phosphorylation sites.
To determine the status of Pax2 phosphorylation, cells were transfected
with epitope-tagged Pax2 and labeled with
[32P]orthophosphate. Immunoprecipitation of Pax2 revealed
one major form of phosphorylated protein (Fig.
1A) and at least one minor form of slightly higher molecular mass. The phospho-Pax2 was excised from the gel and subjected to acid hydrolysis (Fig. 1B).
Amino acids were separated by thin layer chromatography using
phosphotyrosine, -serine, and -threonine markers and subjected to
autoradiography. The immunoprecipitated Pax2 protein was phosphorylated
at both serine and threonine residues, but not at tyrosine residues.
Given the serine/threonine phosphorylation pattern and previously
published reports on Pax6 phosphorylation, we examined the ability of
the three major MAP kinases to phosphorylate Pax2 (Fig.
2). Cells were transfected with
epitope-tagged forms of ERK1, JNK, and p38 MAP kinases and the upstream
activator MEKK1. The kinases were immunoprecipitated and used for
immunocomplex kinase assays with GST-Pax2 and control substrates.
Transfected MEKK1 can activate all three pathways in 293 cells, as
demonstrated by increased phosphorylation of ERK, JNK, and p38 in total
cell lysates (Fig. 2A). However of the immunoprecipitated
kinases, only JNK was able to efficiently phosphorylate GST-Pax2 (Fig.
2B). The ability of activated JNK to phosphorylate Pax2 was
confirmed using a recombinant, constitutively active form of JNK1 (Fig.
2C). The in vitro kinase assay using recombinant
JNK and the GST fusion proteins as substrates indicated that GST-Pax2
was as efficient a substrate as GST-c-Jun (Fig. 2C).
In vitro phosphorylation of GST-Pax2 was also done with an
excess of cold ATP, and the proteins were detected by Western blotting
(Fig. 2D). Using anti-Pax2 antibodies, a slower migrating
form of the GST-Pax2 fusion protein is observed upon phosphorylation
with recombinant JNK. Thus, the antibodies can distinguish between the
unphosphorylated and phosphorylated forms of the GST-Pax2 fusion
protein.
The phosphorylation of Pax2 was also examined directly in cells
co-transfected with MEKK1. To map the domain of phosphorylation more
precisely, carboxyl-terminal deletion constructs of Pax2b were utilized
(Fig. 3). Specific antibodies recognize
the 392-amino acid Pax2b protein, which migrates at ~48 kDa. Upon
co-transfection with MEKK1, a slower migrating Pax2b species was
observed at ~50 kDa in SDS-PAGE gels (Fig. 3B).
Preincubation of the lysates with either calf intestinal phosphatase or
potato acid phosphatase eliminates this slower migrating Pax2b form,
indicating that the shift in mobility is due to phosphorylation,
similar to what was observed in the in vitro assay (Fig.
2D). The MEKK1-dependent, phosphorylated Pax2b
form is seen with carboxyl-terminal deletion constructs 1-373, 1-333,
but not with deletions that contain only amino acids 1-279. Thus,
Pax2b phosphorylation is primarily within the carboxyl-terminal
transactivation domain spanning amino acids 279-415. However,
phosphorylation at additional sites between amino acids 1-279 that
might not affect the mobility of Pax2 in SDS-PAGE gels cannot be ruled
out. Strikingly, this region contains 19 serine and 11 threonine
residues, making definitive assignment of the phosphorylation sites
difficult.
Activation of Pax2 Phosphorylation by Wnt Signals--
During
kidney and neural development, Wnt signaling is known to mediate
inductive interactions. While the canonical Wnt signaling pathway
activates the TCF/LEF family of transcription factors by inhibition of
the GSK3 kinase and translocation of Pax2 Interacts with the JIP1/JNK Signaling Module--
Activation
of the JNK pathway can also occur with via the mixed lineage kinases
(MLK or DLK) in association with the scaffolding proteins of the JIP
family (14, 24, 25). To determine whether Pax2 interacts directly with
this JNK signaling module, cells were co-transfected with Pax2, JIP1,
DLK, and JNK (Fig. 5). Expression of DLK
alone slightly increased the amount of phospho-Pax2 present in total
lysates. At low doses of DLK, Pax2 phosphorylation was further enhanced
by co-expression with JIP1 or JNK. Immunoprecipitation of JIP1 also
pulled down Pax2 and JNK, indicating that at least some Pax2 was
associated with the JNK signaling module. Strikingly, Pax2 could be
co-immunoprecipitated with JIP1 in the absence of DLK, but the amount
of JIP1-associated Pax2 increased significantly upon activation of the
JNK module with DLK. More phosphorylated Pax2 was observed by
expression of DLK, together with exogenous JNK, and this resulted in
even more JIP1-associated Pax2. In the absence of exogenous JIP1,
co-transfection of DLK and JNK produced even more phosphorylated Pax2.
At first this may seem counterintuitive, but transfection of exogenous
JIP1 provides more scaffolding such that individual proteins may not
all assemble on the same scaffold and thus effectively titrate out some
of the activities (14). The data suggest that DLK-dependent
phosphorylation of Pax2 by JNK is mediated by a direct association with
the JNK signaling module, perhaps through interactions with JIP1.
Transactivation of Pax2 Reporter Genes--
To assess the effects
of Pax2 phosphorylation on the transactivation potential, we utilized a
reporter plasmid containing five copies of the PRS4 Pax2b binding
sequence upstream of a minimal promoter and the chloramphenicol
acetyltransferase (CAT) gene. Using a fixed amount of
Pax2b plasmid (125 ng) and increasing amounts of MEKK1,
Pax2-dependent reporter activation increased dramatically
with as little as 50 ng of MEKK1 expression plasmid (Fig.
6A). Pax2 transfection can
stimulate the reporter plasmid activity by 8-10-fold. This increased
to more than 50-fold by co-transfection of 200 ng of MEKK1 expression
plasmid. In the absence of Pax2, MEKK1 had no effect on the expression
of the reporter. Furthermore, a kinase-deficient MEKK1 construct showed only a slight increase at the highest doses. Pax2-dependent
transactivation was also enhanced in the presence of Wnt expression
plasmids (Fig. 6B). Expression of Wnt4, Wnt11, and Wnt7a all
generated a 2-3-fold increase in Pax2-dependent activation
of the reporter gene. Whereas Wnt gene expression alone had no effect
on CAT activity in the absence of Pax2 (data not shown). As reported
previously (3), deletion of the transactivation domain reduced
Pax2-dependent activation (Fig. 6C). A
carboxyl-terminal deletion of amino acids 373-415 still showed a
robust response to MEKK1 although the basal level of
Pax2-dependent activation was down about 2-fold. However, a
carboxyl-terminal deletion of amino acids 333-415 exhibited a further
reduction in basal activation and a loss of responsiveness to MEKK1.
Western blotting indicated that there was some degree of Pax2-(1-333)
phosphorylation in response to MEKK1 (Fig. 3B). However, it
is unlikely that these remaining phosphorylation sites are necessary
for the increased activation potential in response to MEKK1. These data
suggest that the critical phosphorylated residues in Pax2 that mediate
the MEKK1-induced transcriptional activation are located between amino
acids 333 and 415. Similarly, activation of JNK via DLK and JIP
increased the transactivation potential of Pax2 (Fig. 6D).
DLK and Pax2 alone increased reporter activity only slightly. However,
co-transfection of DLK with JIP1 increased the
Pax2-dependent transactivation potential by 3-4-fold. Thus
in all cases examined, the factors that increase JNK activity and
result in increased amounts of Pax2 phosphorylation also significantly enhance the Pax2 dependent transactivation potential of the PRS4 reporter vector.
In this report, we demonstrate that Pax2, a member of the Pax
family of transcription regulators, is phosphorylated by JNK. Also
known as SAPK, JNK phosphorylates a variety of nuclear transcription factors, including c-Jun, Elk1, and ATF2. In particular,
phosphorylation of Ser-63 and Ser-73 of c-Jun results in increased
activity of the AP-1 transcription factor, which consists of a
c-Fos/c-Jun heterodimer (13). Indeed, the sequence around Ser-63 of
c-Jun (LLTSP) is very similar to a conserved serine at
position 393 of the Pax2 protein (LLSSP). However,
phosphorylation of Pax2 may occur at multiple sites. Deletion of the
serine/threonine-rich, carboxyl-terminal transactivation domain
significantly reduces phosphorylation such that a shift in Pax2b
mobility, upon JNK activation, is no longer observed. The
phosphorylated residues that mediate the JNK-dependent
increase in transactivation reside between amino acids 333 and 415 of
the activation domain. Within this region there are 11 serine and 7 threonine residues, of which 6 and 1 respectively are absolutely
conserved within the Pax2/5/8 family. We have begun making point
mutations of these conserved residues. However, preliminary data
indicate that multiple serine substitution must be made before the
MEKK1-dependent increase in transactivation is abrogated
(data not shown).
By definition, the transactivation domain is required for maximal
activation potential of the Pax2 reporter gene, PRS4-CAT, as defined
previously in the absence of exogenous JNK activators. A basal level of
phospho-Pax2 is present that most probably accounts for the 8-10-fold
transactivation potential observed without JNK activation. This basal
levels accounts for the metabolically labeled phospho-Pax2 observed
without JNK activation and the small amount of high molecular weight
Pax2b form observed upon long exposures of Western blots. Basal levels
of activated JNK and phospho-c-Jun are inevitably observed in
proliferating cells stimulated with serum. Because there are presently
no practical JNK inhibtors, we were unable to test whether JNK
activation was absolutely required for Pax2-mediated transactivation.
However, several lines of evidence indicate that JNK is the kinase
responsible for Pax2 phosphorylation, which correlates with increased
transactivation. Of the major MAP kinases, only JNK is able to
phosphorylate Pax2 in the immunolinked kinase assay. Furthermore,
recombinant constitutively active JNK phosphorylates Pax2 in
vitro as efficiently as it phosphorylates c-Jun. Increased JNK
activity leads to increased Pax2 phosphorylation and increased
Pax2-dependent transactivation, regardless of whether JNK
is activated by MEKK1, Wnt signaling, or DLK. Pax2 can associate with
the JNK signaling module as demonstrated by the co-immunoprecipitation of Pax2 with JIP1. Strikingly, activation of the signaling module by
the DLK results in increased JIP1-associated Pax2. A specific inhibitor
of MEK1 (PD98059), which suppresses phosphorylation of the ERK1/2 MAPK,
does not significantly reduce Pax2 phosphorylation nor does it reduce
Pax2-dependent transactivation (data not shown). While JNK
is likely to be the kinase that mediates phosphorylation of Pax2, the
effect on Pax2 activity is less clear. It remains to be determined
whether Pax2 phosphorylation by JNK is merely co-incident with enhanced
activation, whether it is a prerequisite for further modification by
other kinases, or whether there is indeed a causative link to enhanced
Pax2 activation potential.
In the developing kidney and central nervous system, Wnt signaling and
Pax genes play critical roles in establishing patterns and specifying
cell types. During kidney development, Pax2 is expressed in the
metanephric mesenchyme prior to induction by the ureteric bud
epithelium (8). Upon induction, Pax2-expressing cells proliferate,
aggregate around the tips of the ureteric bud, and undergo conversion
to an epithelial phenotype (6, 26). This response to inductive signals
is Pax2-dependent (4, 27) and also requires Wnt4 signaling
(28). That Wnt4 can activate JNK and stimulate
Pax2-dependent gene activation suggests that phosphorylation of Pax2 is an essential component of the induction response. Thus, Pax2 may be an immediate downstream target for inductive signals that can translate these signals by initiating the
epithelial-specific genetic program.
Pax2 and the related genes Pax5 and
Pax8 are also active during neural development, particularly
in the mid-brain/hindbrain junction of the central nervous system
(29-31). Mice carrying targeted mutations for both JNK1 and JNK2 show
regional defects in the developing hindbrain, including decreased
apoptosis prior to neural tube closure in and around the Pax2/5/8
expression domain (32). Thus, modulation of Pax activity by JNK may
also be required for the regulation of neuronal cell number through
selective activation of apoptosis. In any event, more direct studies in
normal and mutant mice are warranted to more precisely determine the
phosphorylation state of Pax proteins during specific stages of development.
We thank A. McMahon for the Wnt4 cDNA,
R. Nusse for the Dvl antibodies, B. Zhang for reagents and advice,
B. Margolis for JIP1 and comments on the manuscript, and I. Levitan for technical assistance.
*
This work was supported by National Institutes of Health
Grants DK54740 and DK54723 (to G. R. D.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Bioscience & Biotechnology, Drexel
University, Philadelphia, PA 19104.
Published, JBC Papers in Press, November 7, 2001, DOI 10.1074/jbc.M109663200
The abbreviations used are:
MAPK, mitogen-activated protein kinase;
JNK/SAPK, c-Jun N-terminal
kinase/stress-activated protein kinase;
MEK, MAPK kinase;
MEKK, MEK
kinase;
CAT, chloramphenicol acetyltransferase;
HA, hemagglutinin.
Phosphorylation of Pax2 by the c-Jun N-terminal Kinase and
Enhanced Pax2-dependent Transcription Activation*
,
§,
,
Pathology and
¶ Medicine, University of Michigan, Ann Arbor,
Michigan 48109
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-tubulin (TUB 2.1, Sigma, 1:10,000).
-glycerophosphate, 0.1 mM orthovanadate, 0.5 mM NaF). The complexes
were incubated for 30 min at 30 °C in 50 µl of kinase buffer
containing 20 µM ATP, 5 µCi of
[
-32P]ATP (3000 Ci/mmol, Amersham Biosciences), 2 µg
of GST-Pax2-(197-415), and 2 µg of either GST-Elk-1 (ERK assay, Cell
Signaling), GST-c-Jun (JNK assay) or GST-ATF-2 (p38 MAPK assay, Cell
Signaling). The reactions were terminated by the addition of 12 µl of
6× SDS loading buffer, 10 mM EGTA and were subjected to
SDS-PAGE followed by transfer to polyvinylidene difluoride membranes
and autoradiography. The amount of kinase that was immunoprecipitated
was assessed by re-immunoblotting of the nitrocellulose. For the
in vitro kinase assay, 50 milliunits of recombinant JNK were
used to phosphorylate equal amounts (2 µg) of GST-Pax2 or GST-c-Jun
in kinase buffer under the same conditions as above or in the presence
of excess cold ATP for Western blotting.
-galactosidase reporter plasmid used to monitor transfection efficiency. 40 h after transfection, cells were
harvested and extracts were prepared and normalized for transfection
efficiency. CAT analysis was performed essentially as described (15).
Percent acetylation was determined by scintillation counting, and a
value of 1.0 was arbitrarily assigned to control parental plasmids. Each experiment was repeated three times and the results presented as
averages ± 1 S.D. from the mean.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (62K):
[in a new window]
Fig. 1.
Phosphoamino acid analysis of Pax2.
A, cells were transfected with vector only (lanes
1 and 4) or with HA-tagged Pax2b (lane 2) or
FLAG-tagged Pax2b (lane 3) and metabolically labeled with
[32P]orthophosphate. Lysates were immunoprecipitated with
anti-HA (lanes 1 and 2) or anti-FLAG (lanes
3 and 4) and analyzed on SDS-PAGE gels. Note major
phosphoprotein migrating at ~48 kDa and slightly higher molecular
mass species at about 50 kDa (arrows). B, amino
acid analysis of 32P-labeled Pax2b immunoprecipitated with
anti-HA (1) or anti-FLAG (2). Markers for phosphoserine, threonine, and
tyrosine were traced from the TLC plates (dotted
lines).

View larger version (26K):
[in a new window]
Fig. 2.
Pax2 is a substrate for JNK. 293 cells
were transfected with either 0.5 µg of Myc-ERK, FLAG-JNK, or Myc-p38
MAPK expression plasmids, with (+) or without (
) 0.1 µg of MEKK1.
A, fraction of the total lysates were analyzed by SDS-PAGE
for activation of MAPK by antibodies against P-ERK1/2, P-JNK, and P-p38
as indicated. Equal loading of lysates was assessed by
anti-
-tubulin. Note activation of all three transfected MAPK in the
presence of MEKK1. B, the remaining lysates were
immunoprecipitated with anti-Myc or anti-FLAG antibodies for in
vitro kinase assays. The kinase reactions contained a mixture of
two substrates. GST-Pax2 was included in all reactions, whereas the
controls contained either GST-Elk, GST-c-Jun, and GST-ATF2 for the ERK,
JNK, and p38 assays respectively. Note that GST-Pax2 is phosphorylated
by JNK only. C, in vitro kinase reaction using
recombinant active JNK and equal amounts of GST-Pax2 or GST-c-Jun as
substrates. D, in vitro kinase reactions using
GST alone or GST-Pax2 fusion proteins and recombinant JNK. The
reactions were done with excess cold ATP and immunoblotted with
anti-Pax2 antibodies. Note the slower migrating GST-Pax2 species in the
JNK-treated reaction (arrow). Because the original antigen
was a Pax2-GST fusion protein, anti-Pax2 antibodies also recognized
GST. The blots shown are from different gels as GST and GST-Pax2
migrate at ~26 kDa and 48 kDa, respectively.

View larger version (32K):
[in a new window]
Fig. 3.
Phosphorylation of the Pax2 transactivation
domain. A, schematic of carboxyl-terminal deletions
used for 293 cell transfections is shown. The DNA binding-paired domain
(DBD), the octapeptide (O), the partial
homeodomain (PHD) and the serine, threonine, tyrosine-rich
transactivation domain (STY) are shown. B,
Western blot analyses of cell lysates from transfected 293 cells. Pax2
constructs were transfected as indicated, with or without 50 ng MEKK1.
A fraction of each lysate was treated with either calf intestinal
phosphotase (CIP) or potato acid phosphatase
(PAP) as indicated. Note slower migrating Pax2b species is
specific for MEKK1-transfected cells and disappears upon phosphatase
treatment.
-catenin to the nucleus,
alternate Wnt signaling pathways can work through the activation of JNK
(16, 17). Particularly during the specification of planar cell polarity
(18), activation of JNK is known to require Disheveled and is uncoupled
from the TCF/LEF pathway (19-21). Given the relationship between Wnt
signaling, kidney development, and JNK activation, we examined the
ability of Wnt proteins to activate JNK and stimulate Pax2
phosphorylation. Cells were co-transfected with expression plasmids for
Wnt4, Wnt11, and Wnt7a and examined for JNK activation and Pax2
phosphorylation (Fig. 4A).
Analysis of total lysates from 293 cells co-transfected with Wnt
expression vectors and Pax2b indicated co-incident phosphorylation of
Pax2, as evidenced by the slower migrating Pax2b isoform (Fig.
4A). Activation of the Wnt pathway results in the slower
migration of the disheveled protein, through phosphorylation at
multiple sites, as reported previously (22, 23). Cells transfected with
each of the three Wnt constructs also exhibited co-incident activation
of JNK (Fig. 4A). The phosphorylation of Pax2 was confirmed by in vivo labeling with [32P]orthophosphate
(Fig. 4B). MEKK1 co-transfected cells showed high levels of
phospho-Pax2, whereas Wnt11 co-transfected cells showed less
phospho-Pax2 but significantly more than cells expressing Pax2 alone.
The data indicate that activation of JNK by either Wnt proteins or
MEKK1 results in increased phosphorylation of Pax2.

View larger version (42K):
[in a new window]
Fig. 4.
Wnt signaling activates JNK and
phosphorylates Pax2. A, Pax2 (125 ng) was
co-transfected with the indicated Wnt expression plasmids (µg) and
lysates were analyzed by Western blotting with anti-Pax2 antibodies.
Note slower migrating Pax2b species (arrow) is prevalent
upon Wnt transfection. Controls include the Pax2 expression plasmid
only (P) and a plasmid vector only (C). Lysates
were also probed with anti-P-JNK, anti-P-ERK, anti-P-p38, and anti-Dvl.
Note activation of JNK and a slower migrating form of Dvl1
(arrow). Equal loading was assessed with anti-
-tubulin.
B, metabolic labeling of Pax2. Cells were transfected with
Pax2bHA and 500 ng Wnt11 or 50 ng MEKK1 as indicated and labeled for
4 h with [32P]orthophosphate. Pax2 was
immunoprecipitated and analyzed by SDS-PAGE. The top panel
is an autoradiograph of the HA immunoprecipitate. The bottom
panel is an immunoblot (IB) with Pax2 antibodies to
show levels of protein. Note that both MEKK1 and Wnt-11 increase Pax2
phosphorylation. Control is plasmid vector only without the Pax2 coding
region.

View larger version (65K):
[in a new window]
Fig. 5.
Pax2 associates with the JNK signaling
module. Cells were transfected with the expression vectors as
indicated. Total amounts of plasmid DNAs per sample were: Pax2b, 400 ng; Myc-JIP1, 500 ng; JNK, 500 ng; DLK, 500 ng. Total cell lysates
(top panels) and anti-Myc immunoprecipitates (bottom
panels) were analyzed by Western blotting with the indicated
antibodies. Note the co-immunoprecipitation of Pax2 and JNK with
Myc-tagged JIP1. Co-expression of JIP1 with DLK and JNK resulted in
maximal Pax2 phosphorylation and increased amounts of JIP1-associated
Pax2.

View larger version (17K):
[in a new window]
Fig. 6.
Transactivation potential of Pax2.
A, MEKK1 increases the transactivation of a Pax2b reporter
gene. Cells were transfected with Pax2 alone or with increasing amounts
of MEKK1, and with the reporter plasmid PRS4-CAT. The control sample
has reporter only and the MEKK1 sample contains the reporter and MEKK1.
B, Wnt signaling increases Pax2-dependent
transactivation. Cells were transfected with Pax2b, PRS4-CAT, and
increasing amounts of Wnt expression plasmids. Wnt expression alone has
no effect on the levels of PRS4-CAT (data not shown). C,
deletion analysis within the Pax2 transactivation domain. Cells were
transfected with full-length Pax2-(1-415) or with deletion constructs
containing the indicated amino acids and with (+) or without (
)
MEKK1. Note that Pax2b-(1-333) shows no increase in activity caused by
MEKK1. D, activation of Pax2-dependent reporter
gene by the DLK/JIP1 signaling module. Note that co-transfection of
JIP1 (100 ng) and DLK (100 ng) increases Pax2-dependent
transactivation 3-4-fold. DLK or JIP1 alone have no effect on reporter
gene expression. For all panels, the mean values of three independent
transfections for CAT activity were shown relative to control
expression plasmid, which was assigned a value of 1.0.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: MSRB1, 4510, 1150 W. Medical Center Dr., Ann Arbor, MI 48109-0650. Tel.: 734-764-6490; Fax: 734-763-6640; E-mail: dressler@umich.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Noll, M.
(1993)
Curr. Opin. Genet. Dev.
3,
595-605
2.
Dorfler, P.,
and Busslinger, M.
(1996)
EMBO J.
15,
1971-1982
3.
Lechner, M. S.,
and Dressler, G. R.
(1996)
J. Biol. Chem.
271,
21088-21093
4.
Torres, M.,
Gomez-Pardo, E.,
Dressler, G. R.,
and Gruss, P.
(1995)
Development
121,
4057-4065
5.
Torres, M.,
Gomez-Pardo, E.,
and Gruss, P.
(1996)
Development
122,
3381-3391
6.
Dressler, G. R.,
and Douglass, E. C.
(1992)
Proc. Natl. Acad. Sci. (U. S. A.)
89,
1179-1183
7.
Dehbi, M.,
Ghahremani, M.,
Lechner, M.,
Dressler, G.,
and Pelletier, J.
(1996)
Oncogene
13,
447-453
8.
Brophy, P. D.,
Ostrom, L.,
Lang, K. M.,
and Dressler, G. R.
(2001)
Development
128,
4747-4756
9.
Song, D. L.,
Chalepakis, G.,
Gruss, P.,
and Joyner, A. L.
(1996)
Development
122,
627-635
10.
Mikkola, I.,
Bruun, J. A.,
Bjorkoy, G.,
Holm, T.,
and Johansen, T.
(1999)
J. Biol. Chem.
274,
15115-15126
11.
Poleev, A.,
Okladnova, O.,
Musti, A. M.,
Schneider, S.,
Royer-Pokora, B.,
and Plachov, D.
(1997)
Eur. J. Biochem.
247,
860-869
12.
Chang, L.,
and Karin, M.
(2001)
Nature
410,
37-40
13.
Davis, R. J.
(2000)
Cell
103,
239-252
14.
Nihalani, D.,
Meyer, D.,
Pajni, S.,
and Holzman, L. B.
(2001)
EMBO J.
20,
3447-3459
15.
Gorman, C. M.,
Moffat, L. F.,
and Howard, B. H.
(1982)
Mol. Cell Biol.
2,
1044-1051
16.
Miller, J. R.,
Hocking, A. M.,
Brown, J. D.,
and Moon, R. T.
(1999)
Oncogene
18,
7860-7872
17.
Wodarz, A.,
and Nusse, R.
(1998)
Annu. Rev. Cell Dev. Biol.
14,
59-88
18.
Mlodzik, M.
(1999)
EMBO J.
18,
6873-6879
19.
Boutros, M.,
and Mlodzik, M.
(1999)
Mech. Dev.
83,
27-37
20.
Moriguchi, T.,
Kawachi, K.,
Kamakura, S.,
Masuyama, N.,
Yamanaka, H.,
Matsumoto, K.,
Kikuchi, A.,
and Nishida, E.
(1999)
J. Biol. Chem.
274,
30957-30962
21.
Li, L.,
Yuan, H.,
Xie, W.,
Mao, J.,
Caruso, A. M.,
McMahon, A.,
Sussman, D. J.,
and Wu, D.
(1999)
J. Biol. Chem.
274,
129-134
22.
Rothbacher, U.,
Laurent, M. N.,
Deardorff, M. A.,
Klein, P. S.,
Cho, K. W.,
and Fraser, S. E.
(2000)
EMBO J.
19,
1010-1022
23.
Lee, J. S.,
Ishimoto, A.,
and Yanagawa, S.
(1999)
J. Biol. Chem.
274,
21464-21470
24.
Yasuda, J.,
Whitmarsh, A. J.,
Cavanagh, J.,
Sharma, M.,
and Davis, R. J.
(1999)
Mol. Cell. Biol.
19,
7245-7254
25.
Whitmarsh, A. J.,
Cavanagh, J.,
Tournier, C.,
Yasuda, J.,
and Davis, R. J.
(1998)
Science
281,
1671-1674
26.
Ryan, G.,
Steele-Perkins, V.,
Morris, J.,
Rauscher, F. J., III.,
and Dressler, G. R.
(1995)
Development
121,
867-875
27.
Rothenpieler, U. W.,
and Dressler, G. R.
(1993)
Development
119,
711-720
28.
Stark, K.,
Vainio, S.,
Vassileva, G.,
and McMahon, A. P.
(1994)
Nature
372,
679-683
29.
Pfeffer, P. L.,
Bouchard, M.,
and Busslinger, M.
(2000)
Development
127,
1017-1028
30.
Schwarz, M.,
Alvarez-Bolado, G.,
Dressler, G.,
Urbanek, P.,
Busslinger, M.,
and Gruss, P.
(1999)
Mech. Dev.
82,
29-39
31.
Bouchard, M.,
Pfeffer, P.,
and Busslinger, M.
(2000)
Development
127,
3703-3713
32.
Kuan, C. Y.,
Yang, D. D.,
Samanta Roy, D. R.,
Davis, R. J.,
Rakic, P.,
and Flavell, R. A.
(1999)
Neuron
22,
667-676
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
G. R. Dressler Epigenetics, Development, and the Kidney J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2060 - 2067. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Amstutz, M. Wachtel, H. Troxler, P. Kleinert, M. Ebauer, T. Haneke, C. Oehler-Janne, D. Fabbro, F. K. Niggli, and B. W. Schafer Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities Cancer Res., May 15, 2008; 68(10): 3767 - 3776. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Benzing, M. Simons, and G. Walz Wnt Signaling in Polycystic Kidney Disease J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1389 - 1398. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bogoyevitch and B. Kobe Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases Microbiol. Mol. Biol. Rev., December 1, 2006; 70(4): 1061 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B Silberstein, K. Van Horn, E. Hrabeta-Robinson, and J. Compton Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system. J. Endocrinol., August 1, 2006; 190(2): 225 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
A G Kayali, A Stotland, K V Gunst, M Kritzik, G Liu, S Dabernat, Y-Q Zhang, W Wu, and N Sarvetnick Growth factor-induced signaling of the pancreatic epithelium J. Endocrinol., April 1, 2005; 185(1): 45 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Cai, N. I. Dmitrieva, J. D. Ferraris, H. L. Brooks, B. W. M. van Balkom, and M. Burg Pax2 expression occurs in renal medullary epithelial cells in vivo and in cell culture, is osmoregulated, and promotes osmotic tolerance PNAS, January 11, 2005; 102(2): 503 - 508. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Zhang, B. Moini, and J. R. Ingelfinger Angiotensin II Increases Pax-2 Expression in Fetal Kidney Cells Via the AT2 Receptor J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1452 - 1465. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Brophy, K. M. Lang, and G. R. Dressler The Secreted Frizzled Related Protein 2 (SFRP2) Gene Is a Target of the Pax2 Transcription Factor J. Biol. Chem., December 26, 2003; 278(52): 52401 - 52405. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Weston, A. Wong, J. P. Hall, M. E.P. Goad, R. A. Flavell, and R. J. Davis JNK initiates a cytokine cascade that causes Pax2 expression and closure of the optic fissure Genes & Dev., May 15, 2003; 17(10): 1271 - 1280. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |